Implications of real world data on the use of first-line pazopanib for the management of metastatic kidney cancer

The following interview with Dr Eric Jonasch, medical oncologist from MD Anderson Cancer Centre in Texas, USA, discusses the implications of real world data on the use of first-line pazopanib for the management of metastatic renal cell carcinoma (RCC). Dr Jonasch was interviewed at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this week.

Watch Dr Jonasch’s interview on Practice Update here

Share this Post!


Related post

  TOP